phrykt

Medifast Inc (MED): who owns it and who trades it

As of Nov 16, 2026, MED insiders reported 2 open-market sales worth $226K and 14 purchases worth $1.7M in the last 12 months, with 100% of the sale value made under pre-set 10b5-1 plans. The largest seller was Daniel R Chard (Director), with $226K. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Medifast

From the latest filings

Overall: more buying than selling. Insiders and famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns MED

112 funds and institutions reported MED shares worth $91.9M at the end of Q2 2026, about 78% of the company. The largest holder is Renaissance Technologies LLC with 7.0%.

Funds and institutions (13F) 78%Everyone else 22%

10 largest owners, by share of the company

Renaissance Technologies LLC7.0%
Steamboat Capital Partners, LLC6.4%
Two Sigma Investments, LP4.3%
Vanguard Capital Management LLC4.0%
Charles Schwab Investment Management Inc3.6%
Sixth Street Partners Management Company, L.P.3.6%
BlackRock, Inc.3.3%
Dimensional Fund Advisors LP3.3%
American Century Companies Inc2.9%
Morgan Stanley2.6%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Renaissance Technologies LLC778,6107.00%$8.3M+1%
Steamboat Capital Partners, LLC706,6996.36%$7.5M-0%
Two Sigma Investments, LP481,3814.33%$5.1M+42%
Vanguard Capital Management LLC446,6144.02%$4.7M+0%
Charles Schwab Investment Management Inc396,9963.57%$4.2M-37%
Sixth Street Partners Management Company, L.P.396,9963.57%$4.2M–
BlackRock, Inc.369,5033.32%$3.9M-61%
Dimensional Fund Advisors LP363,3943.27%$3.9M+0%
American Century Companies Inc318,9112.87%$3.4M+42%
Morgan Stanley292,5082.63%$3.1M-10%
Goldman Sachs Group Inc243,0852.19%$2.6M+59%
Marshall Wace, LLP241,6492.17%$2.6M–
AQR Capital Management LLC236,4342.13%$2.5M+62%
Peapod Lane Capital LLC222,5762.00%$2.4M+2%
Lido Advisors, LLC220,3371.98%$2.3M+20%
Trexquant Investment LP212,6841.91%$2.3M+18%
Jane Street Group, LLC164,8811.48%$1.7M+30%
Commons Capital, LLC149,9161.35%$1.6M+295%
Quinn Opportunity Partners LLC127,1121.14%$1.3MNo change
Geode Capital Management, LLC121,0711.09%$1.3M-52%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, MED insiders reported $1.7M of open-market purchases and $226K of sales. 100% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$1.7M
14 trades, 3 people
Sales, 12 months
$226K
2 trades, 1 people
Sales under a 10b5-1 plan
100%
Share of sale value
Latest trade
Nov 4, 2026
Filed Nov 6, 2026

Purchases and sales by month

$1.4M$1.4MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 4, 2026Parsa KiaiDirectorPurchase661$13.03$8.6KForm 4
Oct 28, 2026Parsa KiaiDirectorPurchase5,399$12.24$66.1KForm 4
Oct 28, 2026Parsa KiaiDirectorPurchase158$12.24$1.9KForm 4
Sep 29, 2026Daniel R ChardDirectorSale plan9,544$11.73$112KForm 4
Sep 28, 2026Daniel R ChardDirectorSale plan9,545$11.98$114KForm 4
Aug 26, 2026Parsa KiaiDirectorPurchase41,975$12.26$515KForm 4
Aug 26, 2026Parsa KiaiDirectorPurchase1,175$12.26$14.4KForm 4
Aug 24, 2026Parsa KiaiDirectorPurchase4,211$12.00$50.5KForm 4
Aug 24, 2026Parsa KiaiDirectorPurchase118$12.00$1.4KForm 4
Aug 20, 2026Parsa KiaiDirectorPurchase41,975$11.60$487KForm 4
Aug 20, 2026Parsa KiaiDirectorPurchase1,175$11.60$13.6KForm 4
Aug 19, 2026Parsa KiaiDirectorPurchase799$11.66$9.3KForm 4
Aug 19, 2026Parsa KiaiDirectorPurchase28,538$11.66$333KForm 4
May 11, 2026Scott SchlackmanDirectorPurchase2,500$12.53$31.3KForm 4
May 8, 2026Scott SchlackmanDirectorPurchase2,500$12.65$31.6KForm 4
Mar 20, 2026Daniel R ChardCEOPurchase17,678$10.11$179KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Parsa KiaiDirector$1.5M–Nov 4, 2026
Daniel R ChardChairman & CEO, Director$179K$226KSep 29, 2026
Scott SchlackmanDirector$63K–May 11, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

MED short interest

High short interest. 11.6% of MED shares are sold short: about 1 share in 9. Over the last 12 reports the number of shares short went down 41%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 1.30M MED shares were sold short, 11.6% of the shares outstanding, up 12.1% from the report before. At the average daily volume of 157,408 shares, buying them all back would take about 8.2 trading days (days to cover).

Shares short, % of all shares

11.6%May 15Oct 3021.2%

Days to cover

8.2May 15Oct 3022.5

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20261.30M11.60%+12%157,4088.2
Oct 15, 20261.16M10.35%+10%101,89411.4
Sep 30, 20261.05M9.42%-43%144,2847.3
Sep 15, 20261.86M16.65%-1%93,00220.0
Aug 31, 20261.88M16.84%+3%124,59915.1
Aug 14, 20261.82M16.32%+23%245,7807.4
Jul 31, 20261.48M13.28%-9%162,0179.2
Jul 15, 20261.64M14.75%+5%174,1679.4
Jun 30, 20261.56M14.04%-28%423,1243.7
Jun 15, 20262.16M19.39%-1%140,55615.3
May 29, 20262.18M19.57%-1%214,19910.2
May 15, 20262.19M19.67%+8%234,2779.3

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Medifast company events

Medifast filed 9 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership). The latest was on Oct 26, 2026.

  1. Oct 26, 2026ResultsReleased financial results. Filing
  2. Aug 3, 2026ResultsReleased financial results. Filing
  3. Jul 17, 2026AnnouncementShared information with investors. Filing
  4. Jun 1, 2026LeadershipJason L. Groves, Esq., the Chief Legal Officer & Corporate Secretary of Medifast, Inc., tendered his resignation from the Company. Filing
  5. May 26, 2026LeadershipAt the Company’s 2026 annual meeting of stockholders, as described below under Item 5.07 of this Current Report on Form 8-K, the stockholders of Medifast, Inc. approved an amendment to the Amended and Restated 2012 Share Incentive Plan primarily to increase the number of shares of the Company's… Filing
  6. May 4, 2026ResultsReleased financial results. Filing
  7. Mar 20, 2026LeadershipThe information included in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 5.02. Filing
  8. Feb 17, 2026ResultsReleased financial results. Filing
  9. Jan 5, 2026LeadershipMedifast, Inc. and Anthony Tyree, a named executive officer of the Company and Chief Business Operations Officer, agreed that Mr. Tyree will depart from his position as Chief Business Operations Officer and any and all other positions he holds as an officer or employee of the Company, effective… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Medifast financials

Famous investors that hold MED

5 of the 50 well-known investors we track reported holding MED in their latest 13F filing. The largest position is Jim Simons's, worth $9.9M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 2026858,513$9.9M0.0%+10%
Paul Tudor Jones · Tudor Investment CorpQ3 2026108,377$1.2M0.0%+43%
Ken Griffin · Citadel AdvisorsQ3 202687,575$1M0.0%+55%
Steve Cohen · Point72 Asset ManagementQ3 202639,097$450K0.0%+86%
Israel Englander · Millennium ManagementQ3 202617,890$206K0.0%-63%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named MED in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Susquehanna Portfolio Strategies, LLC13G/A2.3%
Nov 16, 2026Susquehanna Portfolio Strategies, LLC13G/A2.3%

Questions about Medifast Inc (MED) stock

Who owns the most MED stock?

The largest reported owner of Medifast Inc (MED) is Renaissance Technologies LLC, with 7.0% of the company. In total, 112 funds and institutions reported holding MED at the end of Q2 2026, together about 78% of the shares. See the largest owners.

Are MED insiders buying or selling?

In the last 12 months, MED insiders reported 14 open-market purchases worth $1.7M and 2 sales worth $226K. The latest trade was on Nov 4, 2026. See every trade.

What is the short interest in MED?

As of Oct 30, 2026, 1.30M MED shares were sold short, 11.6% of the shares outstanding, up 12.1% from the report before. At the average daily volume of 157,408 shares, buying them all back would take about 8.2 trading days (days to cover). See the history.

Which famous investors hold MED?

5 of the 50 well-known investors we track reported MED in their latest 13F filing, including Jim Simons, Paul Tudor Jones, Ken Griffin. The largest position is worth $9.9M. See all holders.

Executive pay

Medifast's chief executive was paid a total of $5.6M for the year ended Dec 31, 2025, down 0% from $5.6M the year before. In the last 12 months, Medifast's executives and directors bought $1.7M of stock on the open market and sold $226K.

Chief executive, total pay$5.6MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$2.7MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$1.3MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.